Muraymycin D2
Muraymycin D2 is a peptidyl nucleoside natural product derived from Streptomyces spp., possessing competitive translocase I (MraY) inhibitory activity and antibacterial activity. Muraymycin D2 competitively binds to the nucleotide-binding pocket of the MraY substrate via its nucleoside moiety, and upon binding, induces a conformational change in MraY, blocking lipid I synthesis and inhibiting peptidoglycan biosynthesis. Muraymycin D2 exhibits a Ki of 7.6 nM against Bacillus subtilis and an IC50 of 0.39 nM against Staphylococcus aureus. Muraymycin D2 shows antibacterial activity against Escherichia coli and is capable of breaking persistence in chlamydial infection. Muraymycin D2 can be used for research on bacterial infection-related studies, such as chlamydial infection.
For research use only. We do not sell to patients.
- CAS No.: 474328-38-6
- Formula: C37H61N11O16
- Molecular Weight:915.94
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HEp-2 | MIC |
128 μg/mL
|
Minimal inhibitory concentration of Muraymycin D2 against C. trachomatis D/UW-3/CX in HEp-2 cells, inducing formation of large aberrant bodies, with compound added at 2 h post infection and effects analyzed at 30 h post infection by fluorescence microscopy.
Minimal inhibitory concentration of Muraymycin D2 against C. trachomatis D/UW-3/CX in HEp-2 cells, inducing formation of large aberrant bodies, with compound added at 2 h post infection and effects analyzed at 30 h post infection by fluorescence microscopy.
|
antibiotics13050421 |
In Vitro
Muraymycin D2 competitively inhibits Bacillus subtilis MraY with a Ki of 7.6 nM[1].
Muraymycin D2 (MRY D2) induces enlarged abnormal cells in C. trachomatis D/UW-3/CX, with an MIC of 128 µg/mL[2].
Muraymycin D2 (0.05-0.5 µM; 90 min) inhibits the enzymatic activity of purified C. pneumoniae MraY[2].
Muraymycin D2 (128 µg/mL; 18 h) eradicates persistent C. trachomatis D/UW-3/CX cells in PEN G-induced infection; when applied at the mid-stage, it reduces inclusions in active C. trachomatis D/UW-3/CX infection[2].
Muraymycin D2 binds to A. aeolicus MraY, inducing significant conformational changes and specific binding interactions[1].
Muraymycin D2 exhibits non-Michaelis-Menten kinetics and substrate inhibition with Mur29, giving Km = 41 μM and kcat = 4.0 min−1; it also exhibits non-Michaelis-Menten kinetics and substrate inhibition when reacted with Mur28, with Km = 170 μM and kcat = 5.2 min−1[3].
Muraymycin D2 is regioselectively phosphorylated by the Mg·ATP-dependent 3''-phosphotransferase Mur28 to generate D2-PHOS; the phosphorylated muraymycin D2 exhibits significantly reduced inhibitory activity against S. aureus MraY[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HEp-2 cells infected with C. trachomatis D/UW-3/CX
-
Concentration:128 µg/mL
-
Incubation Time:18 h (added at 12 hpi, analyzed at 30 hpi)
-
Result:Resulted in a 70% reduction in the number of inclusions.\nObserved a 75% reduction in inclusions, of which 83% contained EBs/RBs and 8% had a mixed phenotype.
Chemical Information
-
CAS No. 474328-38-6
-
Molecular Weight 915.94
-
Formula C37H61N11O16
-
SMILES
NC[C@H]([C@H]([C@H]1O)O)O[C@H]1O[C@H]([C@@]2([H])O[C@@H](N3C(NC(C=C3)=O)=O)[C@@H]([C@@H]2O)O)[C@@H](C(O)=O)NCCCNC([C@H](CC(C)C)NC([C@H]([C@@]4([H])NC(N)=NCC4)NC(N[C@H](C(O)=O)C(C)C)=O)=O)=O
-
Structure Classification
-
Initial Source
Streptomyces spp.
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)